Drug Profile


Alternative Names: AZD-6094; HMP-504; HMPL-504; Volitinib

Latest Information Update: 05 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hutchison MediPharma
  • Developer AstraZeneca; Hutchison MediPharma; National Cancer Institute (USA); Samsung Medical Center
  • Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazines; Triazoles
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Adenocarcinoma; Lung cancer; Non-small cell lung cancer
  • Phase I Gastric cancer; Solid tumours

Most Recent Events

  • 29 Jun 2017 Phase-III clinical trials in Renal cell carcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03091192)
  • 29 Jun 2017 Phase-III clinical trials in Renal cell carcinoma (Late-stage disease, Inoperable/Unresectable, Metastatic disease, First-line therapy) in USA (PO) (NCT03091192)
  • 14 Feb 2017 Safety and efficacy data from the phase II trial in Renal cell carcinoma released by AstraZeneca and Hutchison MediPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top